One of the world’s most successful makers of industrial robots plans to turn its hand to creating automatons that help humans.
Last summer, the German robotics firm Kuka—whose bright-orange robots already grace many a factory floor—was acquired by the Chinese household appliance company Midea Group for $5 billion. The purchase reflects a long-standing desire in China to embrace automation. At the time, our own Will Knight explained that the purchase was probably a bid by Midea to roboticize the production of its domestic hardware, but he also speculated that Kuka might help the Chinese firm build domestic robots, too.
Now, the latter prediction is being borne out. In an interview with the Financial Times (paywall), Kuka’s CEO explained that “Midea is not doing any robotics or automation, so Kuka is automation for Midea. And they are very well connected to the consumer industry. So together we want to do consumer robotics.”
It’s not yet clear what form these robots will take. But given Kuka’s heritage, they’re unlikely to be the kind of small companion robots that do little more than talk and wheel around the home. Instead, we might expect the German firm to have ambitions for robots that can load and unload dishwashers, fix you a drink or plateful of food, or help elderly people out of bed. These are complex tasks for machines, but they are gradually becoming more plausible for robots to undertake.
It’s likely to be helpers like this—and not the chirpy, chatting types—that encourage widespread consumer adoption of robots. Earlier this year, market research firm Research and Markets estimated that the personal robotics industry could be worth as much as $34 billion by 2022, growing almost 40 percent per year until then. It argued that robots used for cleaning and elderly care would be the main drivers of that growth.
We shouldn’t expect Kuka’s new machines to be humanoid, then. Indeed, the Financial Times also explains that the firm is “reimagining whether such assistants need to have two arms and a face, or whether they could move and function in some other way.”
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
The baby formula shortage has birthed a shady online marketplace
Desperate parents just want to feed their babies. They’re having to contend with misinformation, price gouging, and scams along the way.
I tried to buy an Olive Garden NFT. All I got was heartburn.
Our newest issue spells out what you need to know about the dizzying world of digital money.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.